Biomarkers in Medicine

Biomarkers in Urological Cancers

Author(s): Bulent Onal*, Mehmet Hamza Gultekin, Muhammed Fatih Simsekoglu, Berin Selcuk and Ahmet Gurbuz

Pp: 37-76 (40)

DOI: 10.2174/9789815040463122010005

* (Excluding Mailing and Handling)


Urological tumours have become one of the most common cancers in the last decade. It is important to apply an approach that evaluates many factors related to the patient and the disease carefully to minimize cancer-associated morbidity and mortality. The clinical use of cancer biomarkers is a valuable part of the clinical management of urological cancers. These biomarkers may lead to optimized detection, treatment, and follow-up of urological cancers. With the development of molecular research, newly developed biomarkers and next-generation sequencing have also contributed to patient management. In this chapter, we will present biomarkers in the most common urological cancers under subheadings of bladder cancer, prostate cancer, kidney cancer, and testicular cancer. Additionally, due to the development that occurred in the next-generation sequencing (NGS), all the above-mentioned malignancies are evaluated with regard to NGS.

Keywords: Biomarkers, Clinical management, Molecular research, Nextgeneration sequencing, Patient management, Urological cancers.

Related Journals
Related Books
© 2024 Bentham Science Publishers | Privacy Policy